Mina Makar, RpH, holds the role of Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals Business Unit at AstraZeneca. In this role he addresses the unmet needs in four inter-related disease areas: metabolism, heart failure, cardiovascular disease and renal diseases, helping to drive AstraZeneca’s ambition to stop, reverse and cure these chronic, progressive and often time devastating diseases by maximising their medicines, delivering innovative solutions and advancing their pipeline. He began his 30-year career in healthcare as a pharmacist and since then has helped to bring important medicines to people who have very few or limited options. Makar joined the CVRM team with deep experience in marketing and sales, payer and access strategies, as well as leadership and engagement. Recognising the deep commitment AstraZeneca has in this important therapy area, Makar looks forward to leading AstraZeneca into the future of CVRM care for the millions of people globally living with these conditions. Makar joined the company more than two decades ago and has had increasing responsibility across the organisation and throughout multiple therapy areas. Most recently, he served as the SVP of US Respiratory & Immunology, delivering significant growth and expansion of the therapy area with several new product launches, including AstraZeneca’s first respiratory biologic, and the delivery of several innovative new approaches in digital health and patient centric support programs.